# N4 Pharma acceleration in understanding of the capabilities of Nuvec

- Link: https://www.directorstalkinterviews.com/n4-pharma-acceleration-in-understanding-of-the-capabilities-of-nuvec/4121023351
- Published: 2021-09-20T07:25:09+01:00
- Author: Giles

**N4 Pharma Plc** (LON:N4P), the specialist pharmaceutical company developing Nuvec
®, a novel delivery system for vaccines and cancer treatments, has announced its
unaudited interim results for the six months ended 30 June 2021.

**Highlights:**

·      Continued strategy to focus on three work streams: optimisation; _in vivo_
studies; and other applications

·      Key focus on establishing collaborations with a view to securing future commercial
agreements, resulting in two Material Transfer Agreements  to assess how well Nuvec
® can bind and be optimised for transfection with each respective party’s proprietary
plasmid:

o  the first of which operates in the gene therapy space

o  the second is a pharmaceutical company developing its own proprietary vaccine
for Covid-19 using a DNA plasmid

·      Continued work with Nanomerics on the use of Nuvec® in respect of the delivery
of TNFalpha in the treatment of cancer, the initial pilot study to assess the tolerance
of different doses has been successful

·      Pilot studies indicated that a lower dose of 10ug pOVA bound to optimised,
monodispersed Nuvec® gave a better result than a 50ug dose of the original, agglomerated
Nuvec® used in previous studies

·      Notifications of intention to grant patents from the European, Australian,
and Japanese patent offices

o  Further strengthening the IP position around Nuvec® with the European Patent 
Office intention to grant a divisional patent in respect of composition

·      Contracted through Medicines Discovery Catapult (“Catapult”) a full-time 
Postdoctoral Researcher

·      Operating loss for the period was £970,628 (30 June 2020: £585,066)

·      Cash balance at period end of approximately £2.54 million

> **Nigel Theobald, Chief Executive Officer of N4 Pharma Plc, commented:** 
> “The first six months of the year has seen an acceleration in our understanding
> of the capabilities of Nuvec® following our optimisation work. This has been coupled
> with our first MTAs which, in turn and together with results elsewhere, led us
> to review the scope of the recently commenced _in vivo_ work with Evotec pushing
> some of this work into the second half of this financial year.
> “Our strategy remains the same as it always has and that is to generate sufficient
> proof of concept data with a view to attracting large pharma and biotech partners
> to enter into collaborations to explore using Nuvec® as their chosen delivery 
> system. The issues facing mRNA Covid vaccines in respect of storage and distribution
> are well known following the Coronavirus pandemic. DNA vaccines are more stable
> than mRNA yet need to use a much higher dose due to the delivery systems currently
> chosen. Demonstrating suitable efficacy whilst addressing the storage and dosage
> issues would, we believe, greatly enhance Nuvec® as a potential delivery tool 
> for vaccines in the eyes of collaborators.
> “With the short-term work programmes likely to provide plenty of data points over
> the next three to six months coupled with the ongoing MTA work we remain cautiously
> optimistic as we seek to commercialise Nuvec®. We continue to be well funded for
> all existing work streams and look forward to analysing the results of studies
> and sharing them with interested parties when they become available.”

Share on:
